Stock Analysis

Insider-Favored Growth Stocks To Watch In January 2025

SZSE:301018
Source: Shutterstock

As global markets navigate choppy waters marked by inflation concerns and political uncertainties, investors are closely watching economic indicators and policy shifts that could influence future growth trajectories. In this environment, stocks with high insider ownership can offer a unique perspective on potential growth opportunities, as insiders often have a deep understanding of their company's long-term prospects.

Top 10 Growth Companies With High Insider Ownership

NameInsider OwnershipEarnings Growth
Duc Giang Chemicals Group (HOSE:DGC)31.4%23.8%
Archean Chemical Industries (NSEI:ACI)22.9%41.2%
Kirloskar Pneumatic (BSE:505283)30.3%26.3%
Clinuvel Pharmaceuticals (ASX:CUV)10.4%25.4%
People & Technology (KOSDAQ:A137400)16.4%37.3%
Medley (TSE:4480)34%27.2%
Brightstar Resources (ASX:BTR)16.2%84.3%
Plenti Group (ASX:PLT)12.8%120.1%
Fulin Precision (SZSE:300432)13.6%66.7%
Findi (ASX:FND)34.8%112.9%

Click here to see the full list of 1455 stocks from our Fast Growing Companies With High Insider Ownership screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Rusta (OM:RUSTA)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Rusta AB (publ) is a retailer of home and leisure products operating in Sweden, Norway, Finland, and Germany, with a market cap of SEK11.40 billion.

Operations: The company's revenue segments are comprised of SEK6.49 billion from Sweden, SEK2.43 billion from Norway, and SEK2.39 billion from other markets.

Insider Ownership: 11.4%

Earnings Growth Forecast: 22.1% p.a.

Rusta demonstrates potential as a growth company with high insider ownership, evidenced by recent insider buying and no substantial selling. Despite slower revenue growth at 9.9% annually compared to the desired 20%, earnings are expected to grow significantly at 22.1% per year, outpacing the Swedish market's 14.3%. The stock trades well below its estimated fair value, while recent board changes may influence strategic direction positively.

OM:RUSTA Earnings and Revenue Growth as at Jan 2025
OM:RUSTA Earnings and Revenue Growth as at Jan 2025

Akeso (SEHK:9926)

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc. is a biopharmaceutical company that focuses on researching, developing, manufacturing, and commercializing antibody drugs with a market cap of HK$51.12 billion.

Operations: The company generates revenue of CN¥1.87 billion from its activities in the research, development, production, and sale of biopharmaceutical products.

Insider Ownership: 19%

Earnings Growth Forecast: 43.8% p.a.

Akeso showcases strong growth potential, with revenue forecasted to increase by 30.1% annually, surpassing the Hong Kong market average. Despite significant insider selling recently, the company remains undervalued at 59.8% below fair value estimates. Akeso's innovative bispecific antibody drugs like cadonilimab and ivonescimab have gained inclusion in China's National Reimbursement Drug List, enhancing their market presence and clinical relevance across multiple cancer indications, which supports its long-term growth trajectory.

SEHK:9926 Earnings and Revenue Growth as at Jan 2025
SEHK:9926 Earnings and Revenue Growth as at Jan 2025

Guangdong Shenling Environmental Systems (SZSE:301018)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Guangdong Shenling Environmental Systems Co., Ltd. operates in the environmental systems industry and has a market cap of CN¥11.02 billion.

Operations: Guangdong Shenling Environmental Systems Co., Ltd. operates in the environmental systems industry with a market cap of CN¥11.02 billion. Revenue segments (in millions of CN¥): [Insert revenue segment details here].

Insider Ownership: 38.7%

Earnings Growth Forecast: 39.6% p.a.

Guangdong Shenling Environmental Systems is poised for substantial growth, with earnings projected to rise significantly by 39.64% annually, outpacing the Chinese market average. Despite recent volatility in share price and a decline in profit margins from 7.1% to 3.8%, insider ownership remains robust, as evidenced by Zhang Yu's acquisition of a 5% stake for CNY 320 million. Revenue growth is expected to exceed market rates at 20.6% annually, indicating strong future potential.

SZSE:301018 Earnings and Revenue Growth as at Jan 2025
SZSE:301018 Earnings and Revenue Growth as at Jan 2025

Turning Ideas Into Actions

Want To Explore Some Alternatives?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com